We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Sensitive Technique Detects Colorectal Cancer in Tissue Samples

By LabMedica International staff writers
Posted on 13 Jul 2015
Print article
Image: Schematics of a DNA-modified, two working-electrode arrays to measure methyltransferase activity from tissue samples (Photo courtesy of Ariel Furst/Caltech).
Image: Schematics of a DNA-modified, two working-electrode arrays to measure methyltransferase activity from tissue samples (Photo courtesy of Ariel Furst/Caltech).
A new sensitive technique has been developed that is capable of detecting colorectal cancer in tissue samples and the method could one day be used in clinical settings for the early diagnosis of colorectal cancer.

The technique measures the activity of a protein called DNA (cytosine-5)-methyltransferase 1(DNMT1) as a possible indicator of a cancerous transformation. DNMT1 is a methyltransferase, an enzyme responsible for DNA methylation which is the addition of a methyl group to one of DNA's bases.

Chemists at the California Institute of Technology (Pasadena, CA, USA) devised an electrochemical platform to measure the activity of DNMT1 in crude tissue samples, those that contain all of the material from a tissue, not just DNA or ribonucleic acid (RNA), for example. Fundamentally, the design of the platform was based on the concept of DNA-mediated charge transport with the idea that DNA can behave like a wire, allowing electrons to flow through it and that the conductivity of that DNA wire is extremely sensitive to mistakes in the DNA itself.

The scientists started with two arrays of gold electrodes, one atop the other, embedded in Teflon blocks and separated by a thin spacer that formed a well for a solution. They attached strands of DNA to the lower electrodes, and then added the broken-down contents of a tissue sample to the solution well. After allowing time for any DNMT1 in the tissue sample to methylate the DNA, they added a restriction enzyme that severed the DNA if no methylation had occurred, and if DNMT1 was inactive. When they applied a current to the lower electrodes, the samples with DNMT1 activity passed the current clear through to the upper electrodes, where the activity could be measured.

Using the platform they measured DNMT1 activity in 10 pairs of human tissue samples, each composed of a colorectal tumor sample and an adjacent healthy tissue from the same patient. When they compared the samples within each pair, they consistently found significantly higher DNMT1 activity, hypermethylation, in the tumorous tissue. Notably, they found little correlation between the amount of DNMT1 in the samples and the presence of cancer; the correlation was with activity.

The authors concluded that DNMT1 hyperactivity as an indicator of cancerous transformation, measured electrochemically, is not clearly observed with the current standard techniques of DNMT1 analysis, including tritium labeling, reverse transcription quantitative polymerase chain reaction (RT-qPCR), and western blotting. Thus the electrochemical platform has the potential to provide a sensitive method of detecting DNMT1-related cancerous transformations, with greater reliability than current DNMT1 analysis techniques.

Jacqueline K. Barton, PhD, a professor of chemistry and senior author of the study, said, “The assay provides a reliable and sensitive measure of hypermethylation. It looks like hypermethylation is good indicator of tumorigenesis, so this technique could provide a useful route to early detection of cancer when hypermethylation is involved.” The study was published on June 25, 2015, in the journal Chemistry & Biology.

Related Links:

California Institute of Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.